PuSH - Publikationsserver des Helmholtz Zentrums München

Export: TXT Text RIS Endnote (RIS) BIB BibTeX
Costanzo, V.* ; Ratre, Y.K.* ; Andretta, E.* ; Acharya, R.* ; Bhaskar, L.V.K.S.* ; Verma, H.K.

A comprehensive review of cancer drug-induced cardiotoxicity in blood cancer patients: Current perspectives and therapeutic strategies.

Curr. Treat. Options Oncol. 25, 465-495 (2024)
Postprint DOI PMC
Open Access Green
Cardiotoxicity has emerged as a serious outcome catalyzed by various therapeutic targets in the field of cancer treatment, which includes chemotherapy, radiation, and targeted therapies. The growing significance of cancer drug-induced cardiotoxicity (CDIC) and radiation-induced cardiotoxicity (CRIC) necessitates immediate attention. This article intricately unveils how cancer treatments cause cardiotoxicity, which is exacerbated by patient-specific risks. In particular, drugs like anthracyclines, alkylating agents, and tyrosine kinase inhibitors pose a risk, along with factors such as hypertension and diabetes. Mechanistic insights into oxidative stress and topoisomerase-II-B inhibition are crucial, while cardiac biomarkers show early damage. Timely intervention and prompt treatment, especially with specific agents like dexrazoxane and beta-blockers, are pivotal in the proactive management of CDIC.
Impact Factor
Scopus SNIP
Altmetric
3.800
0.000
Tags
Anmerkungen
Besondere Publikation
Auf Hompepage verbergern

Zusatzinfos bearbeiten
Eigene Tags bearbeiten
Privat
Eigene Anmerkung bearbeiten
Privat
Auf Publikationslisten für
Homepage nicht anzeigen
Als besondere Publikation
markieren
Publikationstyp Artikel: Journalartikel
Dokumenttyp Review
Schlagwörter Blood Cancer ; Cardiotoxicity ; Cardiovascular Disease ; Immunotherapy ; Therapeutics; Chronic Myeloid-leukemia; Anthracycline-associated Cardiotoxicity; Chronic Lymphocytic-leukemia; Renal-cell Carcinoma; Long-term Survivors; Cardiovascular Toxicity; Hodgkin Lymphoma; Heart-disease; Doxorubicin Cardiotoxicity; Cardiac-disease
Sprache englisch
Veröffentlichungsjahr 2024
HGF-Berichtsjahr 2024
ISSN (print) / ISBN 1527-2729
e-ISSN 1534-6277
Zeitschrift Current Treatment Options in Oncology
Quellenangaben Band: 25, Heft: 4, Seiten: 465-495 Artikelnummer: , Supplement: ,
Verlag Springer
Verlagsort One New York Plaza, Suite 4600, New York, Ny, United States
Begutachtungsstatus Peer reviewed
Institut(e) Institute of Lung Health and Immunity (LHI)
POF Topic(s) 80000 - German Center for Lung Research
Forschungsfeld(er) Lung Research
PSP-Element(e) G-501810-007
DOI 10.1007/s11864-023-01175-z
WOS ID 001164311600002
Scopus ID 85185962129
PubMed ID 38372853
Erfassungsdatum 2024-04-22
[➜Korrektur melden]